Osteoporosis Pipeline Global Therapeutics Landscape Review H1 2015

Press Release   •   Aug 25, 2015 07:56 EDT

Osteoporosis - Pipeline Review, H1 2015 Adds “Osteoporosis - Pipeline Review, H1 2015” which provides an overview of the Osteoporosis pipeline.

This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H1, 2015 Pipeline Review of “Osteoporosis” addition with 101 market data tables and 16 figures, spread across 294 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our professional's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Abiogen Pharma S.p.A., Ablynx NV, Alethia Biotherapeutics Inc., Alize Pharma SAS, Alkem Laboratories Ltd., Amgen Inc., Amura Holdings Limited, Arcarios BV, Astellas Pharma Inc., Bone Medical Limited, Bone Therapeutics SA, Caladrius Biosciences, Inc., Chronos Therapeutics Limited, Chugai Pharmaceutical Co., Ltd., Corium International, Inc., Critical Pharmaceuticals Limited, Daiichi Sankyo Company, Limited, ElexoPharm GmbH, Eli Lilly and Company, EndoCeutics, Inc., Ensoltek Co., Ltd., Enzo Biochem, Inc., F. Hoffmann-La Roche Ltd., Galapagos NV, Glide Pharmaceutical Technologies Limited, Hanmi Pharmaceuticals, Co. Ltd., Haoma Medica Ltd., IMMD Inc., Immunovo BV, Inbiopro Solutions Pvt. Ltd., Kaken Pharmaceutical Co., Ltd., Kolltan Pharmaceuticals, Inc., Lead Discovery Center GmbH, Lupin Limited, Medivir AB, Merck & Co., Inc., Merrion Pharmaceuticals Plc, Novartis AG, Omeros Corporation, Oncobiologics, Inc., Oscotec Inc., Osteologix Holdings Plc, Pantarhei Bioscience BV, Paras Biopharmaceuticals Finland Oy, Pfizer Inc., PhytoHealth Corporation, PolyNovo Limited, R-Pharm, Radius Health, Inc., Richter Gedeon Nyrt., Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Shin Poong Pharm.Co., Ltd., STELIS Biopharma Pvt. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, TAmiRNA GmbH, TSRL, Inc., Uni-Bio Science Group Ltd., Unigene Laboratories, Inc., Ventria Bioscience, Wroclawskie Centrum Badan EIT+ Sp. z o.o. and Zydus Cadila Healthcare Ltd.

Drugs Profile Discussed in this Research:

(aceclofenac + eperisone), AB-25E9, abaloparatide, alendronate sodium, alendronate sodium, alendronate sodium, ALX-0141, AM-3701, AOD-9604, ARC-205, AS-2690168, astrogorgiadiol, bazedoxifene acetate, Biosimilar for Osteoporosis, blosozumab, BN-005, BN-008, calcitonin, CDR-914K058, CDRI-99/373, CH-5036249, denosumab, denosumab biosimilar, denosumab biosimilar, Drug to Inhibit miR-31 for Osteoporosis, Drug to Target miR-002 for Osteoporosis, Drugs for Osteoporosis, Drugs for Postmenopausal Osteoporosis, Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders, DS-1501, esterol, Eu-232, genipin, I-HBD1, ibandronate sodium, IBPB-008IG, IMD-2560, IPS-02 Series, K-671, MAb-7, MIV-711, Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis , Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis, MOR-106, NBS-101, NEP-28, neridronic acid, OCT-1547, odanacatib, ODS-656, Oratonin, OXY-149, Peniel-3000, PHN-031, poncirin, prasterone + acolbifene hydrochloride, PREOB, Protein 1 for Rheumatoid Arthritis and Osteoporosis, Protein 2 for Rheumatoid Arthritis and Osteoporosis, Protein 3 for Rheumatoid Arthritis and Osteoporosis, Proteins to Inhibit RANKL for Breast Cancer and Osteoporosis, PTH-CBD, RDC-5, Recombinant Protein for Osteoporosis, Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis, Recombinant Protein to Inhibit Serine Protease for Bone Disorders and Osteoporosis, romosozumab, RPH-203, S-007-1500, S-101479, S-49288, SBL-001, Small Molecule to Agonize LRP for Osteoporosis, Small Molecule to Agonize PTH-1R for Osteoporosis, Small Molecule to Inhibit Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis, Small Molecule to Modulate Estrogen Receptor for Breast Cancer and Osteoporosis, Small Molecule to Target LGR4 for Cancer and Osteoporosis, Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders, Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders, Small Molecules for Osteopenia and Osteoporosis, Small Molecules for Osteoporosis, Small Molecules for Osteoporosis, Small Molecules for Primary Juvenile Osteoporosis, Small Molecules to Activate CB2 for Osteoporosis, Small Molecules to Agonize Glucocorticoid Receptor for Osteoporosis, Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis, Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis, Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology, Small Molecules to Inhibit Src Tyrosine Kinase for Oncology, Cardiovascular and Metabolic Disorders, Small Molecules to Target Androgen Receptor for Osteoporosis, Sodium Quinate, SP-35454, SR-2595, Stem Cell Therapy for Osteoporosis and Periodontitis, Synthetic Peptide for Osteoporosis and Bone Fracture, TAK-075, teriparatide, teriparatide, teriparatide, teriparatide, teriparatide, teriparatide acetate, teriparatide biosimilar, teriparatide biosimilar, Vaccine to Target Sclerostin for Osteoporosis, VEN-130, VS-105, VS-401, VS-411 and zoledronic acid

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license).


  • The report provides a snapshot of the global therapeutic landscape of Osteoporosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Osteoporosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Osteoporosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Osteoporosis Drugs Market.

Osteoporosis is a painful medical condition which is caused by extreme thinning of bones and porous bone structures as well. It is one of the most common bone diseases and one of the main cause of this trouble is when the rate of formation of new bones in the body is much less as compared to the absorption of old bones in the body. Also, the metabolism of calcium absorption gets disturbed and thus the bones are likely to become porous and brittle and it is characterized by pain in the joints.

The body may droop down and simple routine work like walking and exercising can become extremely difficult. You can find a lot of different osteoporosis drugs that aim at lessening the pain and bettering the condition of the bones. Some of these drugs may have a few adverse effects as there can be a few allergic reactions by these drugs.

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries